Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag234 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 13.06.2026. Verfasst von Yizhou Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Center for Thoracic Tumors of Fujian Province, Fujian Province's special financial funds, Joint Funds for the Innovation of Science and Technology.
Abstract (Originalsprache)
Background
Lymphovascular (LVI) and perineural invasion (PNI) are adverse pathological features in esophageal squamous cell carcinoma (ESCC). We evaluated the prognostic significance of combined LVI/PNI (LNI) after neoadjuvant chemoimmunotherapy (nCIT) and the potential benefit of adjuvant therapy.
Methods
We retrospectively analyzed 473 ESCC patients undergoing nCIT followed by curative resection. LNI status was assessed in resected specimens. Survival outcomes were compared between LNI-positive and -negative patients using propensity score matching and multivariable Cox models. External validation was performed using an independent patient-level dataset.
Results
LNI was present in 21% of patients. LNI-positive patients had worse 3-year overall survival (OS) (49.8% vs 76.4%) and disease-free survival (DFS) (41.7% vs 69.3%), which remained significant after matching. LNI independently predicted inferior OS (hazard ratio [HR] 1.52, P = .022) and DFS (HR 1.40, P = .045). Recurrence occurred more frequently in LNI-positive patients (39.4% vs 19.8%, P < .001), predominantly locoregional. Among LNI-positive patients, adjuvant therapy improved 3-year OS (56.8% vs 32.4%) and DFS (49.7% vs 20.7%; adjusted HR 0.43, P = .002). External validation confirmed these findings, with independent prognostic impact of LNI and benefit from adjuvant therapy.
Conclusions
LNI after nCIT is an independent adverse prognostic factor in ESCC. Patients with these high-risk pathological features have markedly worse outcomes but appear to derive significant benefit from adjuvant therapy, supporting its incorporation into postoperative management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
- Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou, 350001, China.
- National Key Clinical Specialty of Thoracic Surgery, Fuzhou, 350001, China.
- Clinical Research Center, Thoracic Tumors of Fujian Province, Fuzhou, 350001, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
- Department of Thoracic Surgery, Quanzhou First Hospital, Fujian, 362000, China.
ORCID-Profile: Bin Zheng
Förderung
- Clinical Research Center for Thoracic Tumors of Fujian Province
- Fujian Province's special financial funds
- Joint Funds for the Innovation of Science and Technology
- Fujian Province’s special financial funds
Zitieren
APA
Huang, Y., Chen, M., Yang, Z., Cai, B., Zhang, Y., Zhang, S., Zeng, T., Yu, J., Chen, C., & Zheng, B. (2026). Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag234
Vancouver
Huang Y, Chen M, Yang Z, Cai B, Zhang Y, Zhang S, et al. Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag234
BibTeX
@article{Huang2026,
author = {Huang, Yizhou and Chen, Maohui and Yang, Zhenyuan and Cai, Bingqiang and Zhang, Yongcong and Zhang, Shuliang and Zeng, Taidui and Yu, Jun and Chen, Chun and Zheng, Bin},
title = {Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag234}
}
EUVIMED